ORLANDO -- Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit adults with acute myeloid leukemia (AML) compared with conventional induction ...

Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...

An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...

Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of. During a recent visit to the Georgia Cancer Center, CURE sat down for ...

Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...

Intensive chemotherapy provided the longest overall and progression-free survival, especially in blast phase MPN patients. Venclexta-based treatments did not significantly improve progression-free ...

PRINCETON, N.J., Dec. 8, 2025 /PRNewswire/ -- Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, today announced new data ...

A panelist discusses how a large propensity score–matched analysis of 1300 patients aged 60-75 found similar all-cause mortality between intensive chemotherapy and azacitidine plus venetoclax, but ...

Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...